Moneycontrol PRO
HomeAuthorLekha badlani

Lekha Badlani

Research Analyst

Money Control

Apollo Hospitals: A credible profitability road map for pharmacy is the ask

BUSINESS

Apollo Hospitals: A credible profitability road map for pharmacy is the ask

Margin improvement continued in the mature hospitals division, but Apollo 24/7’s operating cost weighed on EBITDA

Global Health: Faster ramp-up in new facilities adds to financial health

BUSINESS

Global Health: Faster ramp-up in new facilities adds to financial health

Strong ramp-up in its newer facilities reflect the growing demand for high-end institutional healthcare facilities

UPL — Limited visibility on debt reduction targets

BUSINESS

UPL — Limited visibility on debt reduction targets

Corporate realignment has generated investor interest, but lowering debt is a prerequisite for rerating

KIMS: Ramp-up of newly acquired entities to be key growth driver

BUSINESS

KIMS: Ramp-up of newly acquired entities to be key growth driver

KIMS presents a play on the structural demand trend for healthcare facilities

Paradeep Phosphate: Watch out for volume uptick, backward integration

BUSINESS

Paradeep Phosphate: Watch out for volume uptick, backward integration

FY24/25 to see backward integration efficiencies kick in. Growth plan is right in place

Coromandel International: The value case for this stock is shaping up well

BUSINESS

Coromandel International: The value case for this stock is shaping up well

A stock well positioned to benefit from growing and continually evolving agri-input space

Sharda Cropchem: Why are we turning positive?

BUSINESS

Sharda Cropchem: Why are we turning positive?

Near-term positive outlook and attractive valuations create room for stock upside

Rallis India: A stock for the next year?

BUSINESS

Rallis India: A stock for the next year?

We see an improvement in Rallis’ business in FY24 and view the recent correction as an opportunity to accumulate for long-term gains

Agri-input sector: Will it get the much-needed boost from the Budget 2023?

BUSINESS

Agri-input sector: Will it get the much-needed boost from the Budget 2023?

Any development that improves affordability to farmers will augur well for agri-input demand and benefit manufacturers

UPL: Wait for the right key to open stock re-rating door

BUSINESS

UPL: Wait for the right key to open stock re-rating door

The stock's current valuation is at a discount to its long-term historical average and remains inexpensive, compared to its peers

Paradeep Phosphate: New capacity creates window for growth

BUSINESS

Paradeep Phosphate: New capacity creates window for growth

Dharmaj Crop Guard: Should you apply for this IPO?

BUSINESS

Dharmaj Crop Guard: Should you apply for this IPO?

Long-term performance and re-rating of this stock depends on successful execution of the planned projects

Dhanuka Agritech: Buyback doesn’t make us a buyer of this stock

BUSINESS

Dhanuka Agritech: Buyback doesn’t make us a buyer of this stock

Margin pressure remains extended, near-term growth triggers remain limited

PI Industries: Standing strong in testing times

BUSINESS

PI Industries: Standing strong in testing times

PI’s superior execution with a solid business model accompanied with surplus cash and backward integration strategies makes it a perfect stock to be bought on declines

Coromandel International: There is a long-term value case for this stock

BUSINESS

Coromandel International: There is a long-term value case for this stock

We resume coverage on Coromandel, with a recommendation to accumulate the stock for long-term gains

Archean Chemical: Company plans to clean balance sheet through IPO

BUSINESS

Archean Chemical: Company plans to clean balance sheet through IPO

Archean Chemical had a checkered history in terms of debt management and struggled to execute its expansion plan one time. A successful IPO, however, can provide a clean slate this time to foray into bromine derivatives

Global Health IPO: Play on regional healthcare demand, subscribe for long term

BUSINESS

Global Health IPO: Play on regional healthcare demand, subscribe for long term

A rebound in patient visits and elective procedures have contributed to the improving economics for hospital chains. Medanta is play on this demand, particularly in the north and east of India

Sumitomo Chemical India: Look beyond the glyphosate usage notification

BUSINESS

Sumitomo Chemical India: Look beyond the glyphosate usage notification

Overall, SCIL has a strong growth potential owing to the healthy launches in the domestic market

Sharda Cropchem: Why are we cautious on the stock despite a steep correction?

BUSINESS

Sharda Cropchem: Why are we cautious on the stock despite a steep correction?

Given the currency trend, we expect margin pressure to sustain in the near term and have reduced our margin assumptions for FY23

Rallis India: Will the stock rally in the long run?

BUSINESS

Rallis India: Will the stock rally in the long run?

SCIL: This MNC-backed agrochemical player has huge growth potential

BUSINESS

SCIL: This MNC-backed agrochemical player has huge growth potential

SCIL shows a strong growth potential owing to the healthy launches in the domestic market

Indian fertiliser sector: Is the pitch fertile for investment?

BUSINESS

Indian fertiliser sector: Is the pitch fertile for investment?

We believe, in the need for better nutrient mix, demand CAGR for complex NPK products will surpass urea

Monsoon Watch | The perils of an extended monsoon

BUSINESS

Monsoon Watch | The perils of an extended monsoon

If the monsoon gets extended, it can impact the kharif crop, thereby potentially putting pressure on food inflation

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347